Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid – Boston Business Journal
Boston Business Journal |
Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid
Boston Business Journal Pfizer has officially entered the race to cure Duchenne muscular dystrophy with gene therapy, joining Cambridge-based Sarepta Therapeutics and Solid Biosciences as the only companies to use the experimental technology on a boy with the muscle-wasting … Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular … Pfizer Begins Clinical Trial With Mini-dystrophin Gene Therapy Candidate Pfizer (PFE) Commences Phase 1b Clinical Trial for Investigational Mini-Dystrophin Gene Therapy, PF-06939926 |
